论文部分内容阅读
利用中效原理观察红景天苷与黄芪注射液协同对人肝癌HepG2细胞增殖的抑制作用。本实验采用Cell Counting Kit-8(CCK-8)法检测红景天苷、黄芪注射液单用及合用时对人肝癌HepG2细胞的抑制作用,用中效方程计算两药的中效浓度,并计算两药合用时的合用指数(CI)。结果发现两种药物单独及联合应用时随着药物剂量增加,其效应也增加。红景天苷的中效浓度(IC50)为4.982 mg/m L,黄芪注射液的中效浓度(IC50)为142.349 mg/m L,两药合用时中效浓度(IC50)为123.271 mg/m L。两药在大剂量合用时效应为协同(CI<1),而在小剂量合用时效应为拮抗(CI>1)。因此,红景天苷或黄芪注射液对人肝癌HepG2细胞有抑制作用,联合应用时效果更佳,两种药物大剂量合用有协同效应,但小剂量合用则表现为拮抗效应。
The inhibitory effect of salidroside and Astragalus injection on the proliferation of HepG2 human hepatoma cells was observed by the principle of neutral effect. In this study, Cell Counting Kit-8 (CCK-8) was used to detect the inhibitory effect of salidroside and astragalus injection on human hepatocellular carcinoma HepG2 cells. The median effective concentration Calculate the co-use index (CI) for both drugs. The results showed that the two drugs alone and in combination with the drug dose increases, the effect also increased. The IC50 of salidroside was 4.982 mg / m L, IC50 of Astragalus membranaceus was 142.349 mg / m L, IC50 of the two drugs was 123.271 mg / m L. The combination of two drugs at high doses was synergistic (CI <1) and antagonistic at low doses (CI> 1). Therefore, salidroside or Astragalus injection of HepG2 cells inhibit human hepatoma, combined effect is better, the two drugs combined with high-dose synergistic effect, but the combination of low-dose showed an antagonistic effect.